论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Li Y, Duo Y, Bi J, Zeng X, Mei L, Bao S, He L, Shan A, Zhang Y, Yu X
Received 28 November 2017
Accepted for publication 25 January 2018
Published 1 March 2018 Volume 2018:13 Pages 1241—1256
DOI https://doi.org/10.2147/IJN.S158290
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Govarthanan Muthusamy
Peer reviewer comments 2
Editor who approved publication: Dr Lei Yang
Introduction: MicroRNA-155 (miR-155) is an oncogenic microRNA, which is upregulated in
many human cancers including colorectal cancer (CRC). Overexpression of miR-155
has been found to regulate several cancer-related pathways, and therefore,
targeting miR-155 may be an effective strategy for cancer therapy. However,
effective and safe delivery of anti-miR-155 to tumors remains challenging for
the clinical applications of anti-miR-155-based therapeutics.
Methods: In this study, we explored the expression of miR-155 and the transcription
factor nuclear factor kappa B (NF-κB) in CRC tissues and cell lines, and the
possible relationship between miR-155 and NF-κB. We further report on
anti-miR-155-loaded mesoporous silica nanoparticles (MSNs) modified with
polymerized dopamine (PDA) and AS1411 aptamer (MSNs-anti-miR-155@PDA-Apt) for
the targeted treatment of CRC.
Results: Results showed that miR-155 is overexpressed in CRC tissues and cell
lines, and there is a positive feedback loop between NF-κB and miR-155.
Compared to the control groups, MSNs-anti-miR-155@PDA-Apt could efficiently
downregulate miR-155 expression in SW480 cells and achieve significantly high
targeting efficiency and enhanced therapeutic effects in both in vivo and in
vitro experiments. Furthermore, inhibition of miR-155 by
MSNs-anti-miR-155@PDA-Apt can enhance the sensitivity of SW480 to
5-fluorouracil chemotherapy.
Conclusion: Thus, our results suggested that MSNs-anti-miR-155@PDA-Apt is a
promising nanoformulation for CRC treatment.
Keywords: miR-155, mesoporous silica nanoparticles, AS1411 aptamer, NF-κB,
5-fluorouracil